DORA-22
Based on 1 Customer Validation
DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 97.67%
- CAS. Nr.: 1088991-95-0
- Formel: C23H22F2N4O2
- Molecular Weight:424.44
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Alle Orexin Receptor (OX Receptor) Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Chemical Information
-
CAS. Nr. 1088991-95-0
-
Appearance Solid
-
Molecular Weight 424.44
-
Formel C23H22F2N4O2
-
Color light brown
-
SMILES
FC1=CC(C(N2C[C@H](COC3=NC=C(F)C=C3)CC[C@H]2C)=O)=C(C4=NC=CC=N4)C=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Reinheit & Dokumentation
-
Data Sheet (267 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Gamble MC, et al. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep. 2020;43(3):zsz241. [Content Brief]
[2]. Lin Y, Ret al. Positive allosteric adenosine A2A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice. Front Pharmacol. 2023;14:1138666. Published 2023 Apr 19. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)